No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	JNJ-95298177 Sensitive: B - Late Trials JNJ-95298177 Sensitive : B	JNJ-95298177 Sensitive: B - Late Trials JNJ-95298177 Sensitive : B
PSMA1 expression	Prostate Cancer	PSMA1 expression	Prostate Cancer	ADCT-212 Sensitive: D – Preclinical ADCT-212 Sensitive : D	ADCT-212 Sensitive: D – Preclinical ADCT-212 Sensitive : D
FOLH1 overexpression	Prostate Cancer	FOLH1 overexpression	Prostate Cancer	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D
PSMA1 expression	Prostate Cancer	PSMA1 expression	Prostate Cancer	MEDI3726 Sensitive: D – Preclinical MEDI3726 Sensitive : D	MEDI3726 Sensitive: D – Preclinical MEDI3726 Sensitive : D
PSMA1 overexpression	Prostate Cancer	PSMA1 overexpression	Prostate Cancer	enzalutamide + PSMA ADC Sensitive: D – Preclinical enzalutamide + PSMA ADC Sensitive : D	enzalutamide + PSMA ADC Sensitive: D – Preclinical enzalutamide + PSMA ADC Sensitive : D
PSMA1 expression	Prostate Cancer	PSMA1 expression	Prostate Cancer	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D

PSMA-targeted antibody-drug conjugate

Associations(6)